Latest News and Press Releases

WESTLAKE VILLAGE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to...

WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...

WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020.  Mr....

3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018°  3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018    •  Afrezza sold to our marketing partner in Brazil for launch was $0.7...

WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its...

WESTLAKE VILLAGE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2019 third quarter and year-to-date financial results and its management will host a...

WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...

WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented...

WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...

2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018  º  2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018  º  2Q 2019 Collaboration and Services Revenue was $8.9 millionAfrezza...